BACKGROUND:
Although cardiac c-kit + cells are being tested in clinical trials, the circumstances that determine lineage differentiation of c-kit + cells in vivo are unknown. Recent findings suggest that endogenous cardiac c-kit + cells rarely contribute cardiomyocytes to the adult heart. We assessed whether various pathological stimuli differentially affect the eventual cell fates of c-kit + cells.
METHODS:
We used single-cell sequencing and genetic lineage tracing of c-kit + cells to determine whether various pathological stimuli would result in different fates of c-kit + cells.
RESULTS:
Single-cell sequencing of cardiac CD45 -c-kit + cells showed innate heterogeneity, indicative of the existence of vascular and mesenchymal c-kit + cells in normal hearts. Cardiac pressure overload resulted in a modest increase in c-kit-derived cardiomyocytes, with significant increases in the numbers of endothelial cells and fibroblasts. Doxorubicin-induced acute cardiotoxicity did not increase c-kit-derived endothelial cell fates but instead induced cardiomyocyte differentiation. Mechanistically, doxorubicin-induced DNA damage in c-kit + cells resulted in expression of p53. Inhibition of p53 blocked cardiomyocyte differentiation in response to doxorubicin, whereas stabilization of p53 was sufficient to increase c-kit-derived cardiomyocyte differentiation.
CONCLUSIONS:
These results demonstrate that different pathological stimuli induce different cell fates of c-kit + cells in vivo. Although the overall rate of cardiomyocyte formation from c-kit + cells is still below clinically relevant levels, we show that p53 is central to the ability of c-kit + cells to adopt cardiomyocyte fates, which could lead to the development of strategies to preferentially generate cardiomyocytes from c-kit + cells.
T he discovery of resident cardiac progenitor cells (CPCs) more than a decade ago has led to the expectation that the heart could be stimulated to regenerate. 1 The most widely published CPC expresses the tyrosine kinase receptor c-kit, although other subtypes of CPCs can be identified based on marker gene expression. 1 In cell culture, these primary cardiac cells, selected for expression of c-kit and the absence of the hematopoietic marker CD45, behave like stem cells, with the ability of clonal derivation, maintenance of an undifferentiated state over multiple population doublings, and multilineage potential. 2 Initially, it was presumed that injection of cultured CPCs would lead to engraftment and differentiation of injected CPCs in situ into distinct cardiac lineages. [3] [4] [5] Although early engraftment and differentiation can be observed, recent studies suggest that injected CPCs do not engraft long term and instead stimulate endogenous regenerative processes. 6, 7 If transdifferentiation is not the mechanism of action for the beneficiary effects of cell therapy, it is critically important to understand how cell therapy positively affects cardiac repair and function. Endogenous CPCs are probable targets of the injected CPCs through undefined paracrine effector molecules and likely play an important role in the beneficial effects observed in response to cell therapy. 8, 9 Therefore, it is important to understand which factors drive endogenous c-kit + cells to adopt differentiated fates. Although cardiac c-kit + cells were identified more than a decade ago, the role that cardiac c-kit + cells play in cardiac homeostasis and regeneration remains controversial. A limiting factor for the field has been the lack of genetic tools that would allow the determination of cell fates of c-kit + cells. We and others have recently published genetic mouse models that allow reliable genetic lineage tracing of c-kit + cells. 10, 11 We initially used these mouse models to determine whether myocardial infarction would lead to increased cardiomyocyte differentiation. However, the overall numbers of cardiomyocytes that were generated by c-kit + cells were low and considered of no physiological relevance. 10, 11 The goal of the present study was to determine whether different pathological stimuli induced different cellular fates of endogenous cardiac c-kit + cells. Here, we identified different clusters of freshly isolated cardiac c-kit + cells based on single-cell sequencing and demonstrate that cardiac pressure overload results in a balanced stimulation of cardiomyocyte, endothelial, and fibroblast cell fates. We further report that anthracycline-induced cardiomyopathy specifically enhances cardiomyocyte fates. Mechanistically, we identified p53 as a central regulator of cardiomyocyte fates in response to anthracyclines.
METHODS
An expanded Methods section is available in the online-only Data Supplement. All data, methods used in the analysis, and materials are available for purposes of reproducing the results by contacting the corresponding author.
Animals

Kit
+/Cre-IRES-nGFP mice and Kit +/MerCreMer (Kit
) as well as reporter mice were previously reported. 10 Super p53 mice (B6;CBA-Tg(Trp53)1Srn/J) were purchased from the Jackson Laboratory. 12 Cardiac pressure overload in mice was induced via transverse aortic constriction (TAC) as described previously. 13 All animal procedures were performed in accordance with institutional guidelines and approved by the University of Minnesota Institutional Animal Care and Use Committee.
Pharmacological Treatments
Details about dosing and administration of tamoxifen, doxorubicin (DOX), RITA (Reactivation of p53 and Induction of Tumor cell Apoptosis), and pifithrin-α are available in the online-only Data Supplement.
Histological Analysis
Histological stains were performed on cryoembedded tissues according to well-established procedures. An overview of antibodies used is provided in Table I in the online-only Data Supplement.
RNA Sequencing Analysis
Cardiac CD45 -c-kit + cells were isolated from adult C57BL/6J mice after a published protocol with minor modifications. 14 Cells were sorted by magnetic-activated cell sorting, followed
Clinical Perspective
What Is New?
• This is 1 of the first studies to show that cardiac c-kit + cells behave differently in response to various stimuli and doxorubicin stimulates them to adopt a cardiomyocyte fate.
• This study used single-cell sequencing to show innate heterogeneity within c-kit + cells, where these have either an endothelial or a mesenchymal identity.
• This study showed an important role for p53 in the differentiation of c-kit + cells to cardiomyocyte fates.
What Are the Clinical Implications?
• This study shows that endogenous cardiac cells can give rise to cardiomyocytes under specific circumstances, such as in response to doxorubicin, which may ultimately lead to the discovery of specific drugs or treatments that could enhance new cardiomyocyte formation in the adult heart to combat heart failure.
• Although we show that cardiomyocytes can be derived from endogenous c-kit + cells, the rates are currently too low to be therapeutically meaningful.
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by propidium iodide staining and MoFlo XDP (Beckman Coulter) mediated sorting of live cells. Sorted cells were immediately stained for live/dead and used for single-cell capture using the Fluidigm C1 capture system on an integrated fluidics circuit optimized for capture of cells sized 5 to 10 µm. Based on acquired images, we selected single live cells to proceed with library preparation according to the Fluidigm protocol. 15 Raw single-cell RNA sequencing data were plotted in a matrix consisting of 23 425 genes and 405 cells. We used t-Distributed Stochastic Neighbor Embedding to visualize the data and clustered cells into 4 clusters using the partitioning around medoids clustering algorithm. The number of cluster groups is determined based on gap statistic. 16 Further details on single-cell and bulk RNA sequencing analyses are provided in the onlineonly Data Supplement. Sequencing data have been deposited at BioProject under accession number PRJNA412028.
Statistics
Results are described as mean±SEM. Student t tests were performed when comparing 2 conditions, and an analysis of variance followed by Tukey's honest significant difference post hoc analysis was used for multiple condition comparison. A P value <0.05 was considered significant.
RESULTS
Single-Cell RNA Seq Shows Heterogeneity of c-kit + Cells in Vivo
Expression of the tyrosine kinase receptor c-kit has been used extensively to select for cells that display characteristics of CPCs. 4 Clonal assays in cell culture clearly show that CPCs can be identified from the adult heart and have the ability to differentiate into cardiomyocytes, endothelial cells, and smooth muscle cells, although differentiation to beating cardiomyocytes is typically not observed in vitro. 2 ). Clustering analysis identified 4 main clusters, 3 in close proximity to each other and 1 more distinct cluster ( Figure 1A) . We analyzed the gene expression that is indicative of lineage commitment within each of these clusters. This analysis defined an endothelial cell identity for cells in groups 1, 3, and 4 and a mesenchymal cell identity for cells in group 2 ( Figure 1B and 1C). We did not detect a specific cluster of cells that showed expression of cardiomyocyte characteristic genes ( Figure 1D ). We performed coclustering with previously published RNA seq datasets of endothelial cells, fibroblasts, and cardiomyocytes. This showed close proximity of cells in groups 1, 3, and 4 to endothelial cells and proximity of group 2 to fibroblasts, whereas cardiomyocytes did not cluster together and did not show a proximity to any of the identified clusters (Figure IIA 
Cardiac Pressure Overload Stimulates Endothelial and Fibroblast Fates
To assess whether cardiac pressure overload would stimulate specific cell fates of c-kit + cells, we utilized our recently published tamoxifen-inducible lineage-tracing mouse model, Kit +/MCM X Rosa26-Green Fluorescent Protein (R-GFP) ( Figure 2A ). For all tracing experiments, we provided tamoxifen before the onset of subsequent treatments to reduce the potential of ectopic activation of lineage tracing within cardiomyocytes. We induced cardiac pressure overload by constricting the transverse aorta (TAC) between the brachiocephalic and left carotid artery as previously described. 13 Two weeks after TAC, we observed a significant increase in heart weight to body weight ratios in both control and Kit +/MCM X R-GFP mice, indicative of cardiac hypertrophy and a mild reduction in cardiac function ( Figure 2B ). Next, we quantified the percentage of GFP + cardiomyocytes in sham and TAC-treated Kit +/MCM X R-GFP mice and noted a significant 3-fold increase to 0.011% compared with experimental controls ( Figure 2C ). We verified the identity of GFP + cardiomyocytes using immunohistochemistry and costaining with the well-known cardiac marker desmin ( Figure 2D ). We next used dual fluorescent reporter mice Kit +/MCM R-mTmG, where membrane-targeted Tomato is expressed in all cells but in response to Cre-mediated recombination membrane-targeted GFP becomes expressed ( Figure 2E ). This mouse model was used to test whether the increase in GFP + cardiomyocytes was a result of fusion or de novo cardiomyocyte formation. When c-kit + cells recombine in response to tamoxifen and then differentiate into cardiomyocytes, these cardiomyocytes will be mGFP + only. However, when c-kitderived cells fuse with already existing cardiomyocytes, dual mTom and mGFP (yellow) expression results. We again treated mice with tamoxifen before the onset of TAC. We could identify examples of both mGFP + -only cardiomyocytes as well as dual mGFP + and mTom + cardiomyocytes ( Figure 2F ), but we did not see a statistically significant difference in the fraction of mGFP + cardiomyocytes that was only mGFP + versus dual mGFP + and mTom + ( Figure 2G ). We next tested the abundance of other cardiac lineages in response to TAC and found It is interesting to note that both perivascular and interstitial areas of fibrosis showed extensive overlap between Vimentin staining and GFP signal. Clearly, TAC enhanced c-kit-derived cell fates of cardiomyocytes, endothelial cells, and fibroblasts. However, cardiomyocyte fates were only increased 3-fold to reach 0.011% of total cardiomyocytes, similar to our previously published response to experimental myocardial infarction. 10 When fusion was taken into account, the overall addition of new cardiomyocytes from c-kit + cells is likely closer to 0.0028% versus 0.0006 in sham-operated animals.
Anthracycline-Induced Cardiomyopathy Stimulates Cardiomyocyte Differentiation
Next, we used the inducible Kit +/MCM X R-GFP mice to determine the effect of acute DOX-induced cardiomyopathy on c-kit + -dependent lineage commitment. Again, we treated mice with tamoxifen and withdrew the tamoxifen-laden chow well before the onset of injury to avoid potential activation of Kit expression in cardiomyocytes ( Figure 4A ). We found a significant increase in GFP + cardiomyocytes in response to DOX (>30-fold to 0.11% of total cardiomyocytes). GFP + cardiomyocytes were identified by native GFP fluorescence ( Figure 4C ) and by costaining with the cardiac marker α-actinin ( Figure 4D ). The GFP + cardiomyocytes appeared to be well connected with the surrounding myocardium, with proper Connexin 43 expression, and were essentially indistinguishable from GFP -cardiomyocytes (Figure IVA in the online-only Data Supplement). To rule out the possibility that DOX could activate nuclear translocation of the MerCreMer fusion protein or induce recombination of the reporter locus, we treated Kit +/MCM X R-GFP mice with DOX without prior tamoxifen treatment. It is important to note that DOX alone could not activate R-GFP because no GFP + cells were observed in the hearts of mice treated with DOX. Next, we used the double fluorescent reporter mouse line, Kit +/MCM R-mTmG, to test whether DOX induced new cardiomyocyte formation from c-kit + cells ( Figure 4E ). We identified both mGFP + only and dual mGFP + and mTom + cardiomyocytes but now measured a significant increase in the fraction of mGFP + -only cardiomyocytes in response to DOX, indicative of newly differentiated cardiomyocytes Based on these data, we calculated new cardiomyocyte formation from c-kit + cells to be ≈0.00043% in saline treated mice and 0.046% in DOX-treated mice.
To assess whether DOX also enhanced the commitment of c-kit + cells toward the endothelial lineage, we used a separate mouse line, Kit +/Cre-IRES-nGFP , where Cre recombinase followed by a nuclear-targeted GFP cDNA was inserted into the murine Kit locus (Figure VA in the online-only Data Supplement). The nuclear localized GFP provides a real-time readout of active c-kit expression. We treated these mice with DOX and found no difference in the fraction of c-kit-expressing cells that costained with the vascular differentiation marker Kdr ( Figure VB and VC in the online-only Data Supplement), suggesting that DOX does not enhance the endothelial fate of c-kit + cells. Indeed, when we measured the fraction of endothelial cells that were GFP + in Kit +/MCM X R-GFP mice (c-kit + -derived endothelial cells), we observed similar percentages in both saline-and DOX-treated mice ( Figure 5A and 5B). To assess whether DOX stimulated the expression of cardiac transcription factors in c-kit + cells, we treated C57BL/6 mice with a single dose of DOX and stained for the cardiac transcription factor Nkx2-5 3 days later ( Figure 5C ). Although the level of Nkx2-5 expression is clearly lower than that in adult cardiomyocytes, a significant increase occurred in the abundance of c-kit + Nkx2-5 + double-positive cells in response to DOX ( Figure 5D ). We further examined the expression of GATA4, which showed an increase by day 7 after DOX treatment, which was confirmed in Kit +/Cre-IRES-nGFP mice ( Figure 5E and 5F and Figure VD and VE in the online-only Data Supplement). These data indicate that DOX stimulates c-kit + cells to preferentially differentiate toward cardiomyocyte fates while maintaining the levels of endothelial cell fates.
Anthracycline Stimulates p53 Activation, Which Mediates Differentiation
Anthracyclines are well known for their cardiotoxicity, and indeed we showed significant cardiac dysfunction after a cumulative dose of 20 mg/kg DOX (Table II in the online-only Data Supplement). It was possible that paracrine effectors, released because of extensive cardiac damage, exerted stimulatory effects on c-kit + cells to differentiate into cardiomyocytes, so we next tested whether the effects of DOX on c-kit + cells were independent of cardiac dysfunction. We treated Kit +/MCM X R-GFP mice with a single low-dose DOX at 5 or 10 mg/ kg and measured c-kit-derived GFP + cardiomyocytes 4 weeks later. We observed a significant dose-dependent increase in c-kit-derived cardiomyocytes in response to these lower dosages, which did not cause significant changes in left ventricular fractional shortening (Figure 6A and Table II in the online-only Data Supplement). To further rule out spurious activation of the Kit promoter within cardiomyocytes as a potential reason for increased GFP + cardiomyocytes, we assessed the percentage of GFP + cardiomyocytes at multiple time points after DOX administration. After a single dose of DOX at 10 mg/kg, we measured the percentage of GFP + cardiomyocytes in different mice for each time point after DOX injection and noticed a significant increase starting 2 weeks after DOX administration ( Figure 6B ). These data are consistent with the differentiation of ckit + cells rather than Kit expression within cardiomyocytes as the mechanism for the appearance of GFP + cardiomyocytes. Next, we began to address the underlying mechanism for DOX-induced cardiomyocyte differentiation of c-kit + cells. The main effect of DOX as a chemotherapeutic agent is to cause DNA damage, which in turn activates p53 to repair this damage or, alternatively, induces apoptosis. To further rule out that cardiomyocyte differentiation in response to DOX was not the consequence of extensive cardiac damage, we tested the effect of Etoposide, a different genotoxic chemotherapeutic that also induces DNA damage and p53 activation but is not known to cause cardiac dysfunction. Indeed, Etoposide also significantly enhanced c-kit-derived cardiomyocyte formation ( Figure 6C ). These results suggest that the activation of DNA repair mechanisms in response to DNA damage might be important in mediating cardiomyocyte differentiation. To test this hypothesis, we used Kit +/Cre-IRES-nGFP mice and treated them with a single dose of 10 mg/kg DOX. Twenty-four hours after DOX treatment, we harvested hearts and stained them for p53, a critical upstream response gene that is activated after DNA damage. In response to DOX, a significant increase occurred in the fraction of c-kit-ex- pressing cells that coexpressed p53 ( Figure 6D and 6E) . We also observed activation of DNA repair mechanisms within c-kit-expressing cells by costaining with γ-H2Ax and 53BP1, mediators of the DNA repair machinery (Figure VIA and VIB in the online-only Data Supplement). Especially in rapidly dividing cancer cells, the DNA damage induced by Etoposide or DOX stimulates apoptotic cell death. Because DNA damage might also lead to apoptosis, we wanted to rule out this possibility in the c-kit-expressing cells. We used cultured primary c-kit + cells and compared them to 3T3 fibroblasts. We treated both cell types with DOX and measured the presence of DNA damage 4 and 24 hours after the addition of DOX using Comet assays ( Figure 6F ). As expected, DOX induced DNA damage in both 3T3 and c-kit + cells at 4 hours. However, c-kit + cells appeared to be able to repair the DNA damage by 24 hours, whereas 3T3 cells remained positive for the presence of DNA damage at 24 hours. Western blotting showed that both 3T3 and c-kit + cells activate p53 in response to DOX, but only 3T3 cells went on to express cleaved caspase 3, showing activation of apoptosis, whereas c-kit + cells did not activate caspase 3 ( Figure 6G ). We further confirmed these findings with freshly isolated noncardiomyocytes that were depleted from c-kit + versus adult c-kit + cells ( Figure  VIC in the online-only Data Supplement). Moreover, we verified that endogenous c-kit + cells were not depleted from the heart in response to DOX. We stained cardiac sections with antibodies against CD45, CD31, and c-kit and quantified the number of CD31 Because both 3T3 and c-kit + cells activated p53 in response to DOX, we next tested whether p53 was critical ORIGINAL RESEARCH ARTICLE in mediating cardiomyocyte differentiation from endogenous c-kit + cells. To examine this possibility, we used the specific p53 inhibitor pifithrin-α and injected this inhibitor daily in DOX-treated mice. 22 Blocking p53-mediated gene transcription completely blocked the appearance of GFP + cardiomyocytes and reverted the numbers back to saline-treated controls ( Figure 7A ). To further confirm that we were correctly counting adult cardiomyocytes from histological sections, we performed adult cardiomyocyte isolations from mice treated with DOX alone or DOX in combination with daily pifithrin-α injections. In response to DOX, we quantified 0.1% of isolated adult cardiomyocytes to be GFP + , whereas pifithrin-α treated mice showed significantly lower levels, entirely consistent with our quantifications from histological sections ( Figure 7B and 7C) . These findings show that activation of p53 is required for cardiomyocyte differentiation of c-kit + cells in response to DOX. If indeed p53 was mediating the differentiation of c-kit + cells to cardiomyocytes, then we hypothesized that stabilization of p53 might be sufficient to induce this differentiation event. To test this hypothesis, we used the small-molecule RITA, which blocks the interaction between p53 and MDM-2, thereby stabilizing p53. 23 We again verified that RITA alone, without prior tamoxifen treatment, was unable to activate the genetic lineage-tracing system. We injected RITA twice per week in Kit +/MCM X R-GFP mice for 4 weeks and found a significant 12-fold increase in the numbers of GFP + cardiomyocytes, indicating that stabilization of p53 is sufficient to drive cardiomyocyte differentiation of c-kit + cells ( Figure 7D and 7E) . RITA stimulation by itself does not cause DNA damage, indicating that p53 and not DNA damage is the main mediator of cardiomyocyte differentiation from c-kit + cells (Figure VIE in the online-only Data Supplement). We again assessed the percentage of GFP + cardiomyocytes in response to RITA administration at multiple time points to verify that RITA treatment results in the differentiation of c-kit + cells as opposed to activation of the Kit gene within cardiomyocytes ( Figure 7F ). To further as- sess a role for p53 in the differentiation of c-kit + cells into cardiomyocytes, we cross-bred mice that express 1 additional copy of p53 from a transgenic construct (super p53) with Kit +/MCM X R-GFP mice. It is interesting to note that 1 additional copy of p53 was sufficient to increase the number of GFP + cardiomyocytes derived from c-kit + cells ( Figure 7G ). To begin to understand how p53 might be responsible for the cardiogenic potential of ckit + cells, we performed luciferase assays using the atrial natriuretic factor promoter. We transfected human embryonic kidney 293 cells with this promoter and either Nkx2-5, p53, or Nkx2-5 and p53 expression plasmids. Combined transfection of half the amount of Nkx2-5 and p53 together potentiated the transcriptional activation of the atrial natriuretic factor promoter ( Figure 7H ). These results clearly establish a central role for p53 in the differentiation of c-kit + cells toward cardiomyocytes. Last, to explore how DOX treatment affects gene expression within c-kit + cells, we performed RNA sequencing on freshly isolated CD45 -c-kit + cells 4 days after saline or DOX injection ( Figure 8A and 8B). We identified 220 significant differences in gene expression between CD45
c-kit + cells harvested from saline-and DOX-treated mice, including cardiac genes Myotilin and Nppb (Table III in the online-only Data Supplement). We performed quantitative polymerase chain reaction on freshly isolated CD45 -c-kit + cells 4 days after saline or DOX treatment for a number of cardiogenic and other candidate genes. Overall, these results show consistent upregulation of cardiogenic genes, such as the transcription factor Nkx2-5, fetal genes Nppa and Nppb, as well as cardiac myosins Myh6 and Myh7, indicative of the expression of cardiomyocyte specific genes and ongoing differentiation toward a cardiomyocyte fate ( Figure 8C and Table IV in the online-only Data Supplement).
DISCUSSION
Cardiac progenitor cells likely play important roles in normal homeostasis of the heart and response to car- diac injury, although their precise function in homeostasis or repair is unclear, and their contribution to cardiomyocytes has been questioned. 10, 11, 20, 21, [24] [25] [26] Our results showed that endogenous c-kit-expressing cells can be stimulated to generate cardiomyocytes, albeit at relatively low rates. It is surprising that we found that anthracycline-induced cardiomyopathy produced the most conducive stimulus to enhance lineage-traced cardiomyocytes >30-fold to reach 0.11% of total cardiomyocytes. To begin to assess why anthracyclines stimulate c-kit + cells toward cardiomyocyte fates, we defined p53 as a central regulator in the DNA damage response program 27 as well as an important mediator of the differentiation of c-kit + cells toward a cardiomyocyte fate. This was evident from blocking p53-mediated gene transcription in the setting of DOX-induced cardiomyopathy, where p53 appeared to be necessary for the increase in new cardiomyocyte formation. Moreover, when we used the small-molecule RITA to stabilize p53, a 12-fold increase in c-kit + cell-derived cardiomyocytes occurred. Stabilization of p53 using RITA did not give rise to DNA damage, indicating that p53 by itself is sufficient to enhance cardiomyocyte differentiation from c-kit + cells. This finding was further substantiated by cross-breeding to super p53 transgenic mice, in which 1 additional copy of p53 was sufficient to increase the number of lineage-traced cardiomyocytes. 12 Moreover, we showed that p53 could potentiate the ability of Nkx2-5 to activate the atrial natriuretic factor promoter. These results showed that p53 plays a crucial role in the differentiation of c-kit + cells toward cardiomyocytes. Although p53 is typically viewed as a regulator of cell death, its role in differentiation has become evident over the past couple of years.
28,29 p53-null mice develop normally and succumb to malignancies by 3 to 4 months of age. 30 A number of recent findings have shown a critical role for p53 in regulating differentiation. It plays an initiating step in suppressing pluripotency by inhibiting factors, such as Nanog. 31 In addition, p53 can regulate miR-34a and miR-145, resulting in the downregulation of pluripotency factors Oct4, Klf4, Lin28A, and Sox2. 29 Furthermore, p53 plays a crucial role in maintaining hematopoietic stem cell quiescence. 32 Further evidence for an important role of p53 in the heart comes from the identification of p53 as an inhibitor of Hif1 activity. 33 Increased expression of p53 resulted in reduced angiogenesis after pressure overload, ultimately leading to heart failure. It is interesting to note that DOX has been shown to result in impaired vascularization, entirely consistent with our findings that endothelial fates are not enhanced in response to DOX. 34 However, increased expression of p53 in fibroblasts actually increased vascularization in response to myocardial infarction by converting fibroblasts to endothelial cells. 35 These results clearly showed that p53 plays important roles in regulating the heart's response to stimuli, although the cellular context is likely to be important for the precise outcome and regulation of new cell formation. Moreover, the precise role of p53 in mediating cardiomyocyte differentiation of c-kit + cells as well as downstream pathways remains to be determined.
It is intriguing that different stimuli, such as pressure overload stimulation or anthracycline stimulation, have such divergent effects on the eventual cell fate of c-kit + cells. This finding suggests that specific stimuli must promote cardiomyocyte fates such as p53. One potential caveat for our findings, however, comes from a recent publication suggesting that the c-kit gene could be acti- vated within cardiomyocytes. 19, 21 If this were indeed the case, it could potentially lead to overestimation of the levels of new cardiomyocyte formation from c-kit + cells. The basis for claiming c-kit could be expressed in cardiomyocytes from the early activation of recombination in cardiomyocytes in response to tamoxifen addition. Only 24 hours after tamoxifen addition, GFP expression in cardiomyocytes was already observed, a time window that is clearly insufficient to allow for active differentiation, although fusion might explain such timing. 21 Nevertheless, the expression of c-kit within cardiomyocytes was deemed a more likely explanation. However, it is noteworthy that additional knock-in mouse lines that express fluorescently tagged histone proteins whenever the Kit promoter is activated never show cardiomyocytes to express these fluorescent histone proteins. 20 One critical strategy we followed to avoid this potential bias was to consistently withdraw tamoxifen before the onset of the experiments. We waited ≥72 hours between withdrawing tamoxifen and initiation of the experiment, which is >5 times the elimination half-life in mice. 36 Further convincing evidence comes from our experiment where we precisely quantified the fraction of GFP + cardiomyocytes at multiple time points after a single administration of DOX. Up to 7 days after DOX administration, we see no difference between DOX-and saline-treated numbers of GFP + cardiomyocytes. We only began to observe a significant increase between 1 and 2 weeks after DOX administration, which is inconsistent with activation of the Kit promoter in cardiomyocytes in our experiments and clearly suggests differentiation of c-kit + cells. Therefore, we are confident that our findings show actual c-kit + cell-dependent differentiation and not activation of the Kit promoter in cardiomyocytes. Our single-cell sequencing data show no differences between c-kit + cells harvested from wild-type or lineage-tracing mice, showing that the lineage-tracing mouse does not have some sort of inherent genetic defect to explain why so few c-kit + cell-derived cardiomyocytes are seen under homeostatic conditions. 10, 11, 20, 21 Single-cell sequencing is revolutionizing our understanding of the precise cellular content of organs. Here, we performed single-cell sequencing on c-kit + cells harvested from adult hearts to show a distribution into 2 main clusters of endothelial-and mesenchymal-like cells. We did not detect a specific dedicated cardiomyocyte cardiac progenitor cell, further supporting the notion that c-kit + cells don't contribute large numbers of cardiomyocytes under homeostatic conditions. Although the expression of transcription factors that are likely indicative of lineage commitment in partially differentiated c-kit + cells is often reported, it remains unclear whether these cells actually progressed to differentiate and give rise to new cardiac cells. 4, 37 We used genetic lineage tracing to show that, under specific circumstances, ckit + cells can give rise to cardiomyocytes. Whether these cardiomyocytes were derived from specific subgroups of c-kit + cells is unclear at this point. Future single-cell studies, performed after specific stimuli, might provide additional insight. Although these results are encouraging for the possibility of generating new cardiomyocytes from c-kit + cells, the precise roles of p53 and DNA damage herein need to be further studied. A DNA damage checkpoint, independent of p53-mediated gene transcription, which determines self-renewal versus differentiation has been proposed in hematopoietic stem cells. 38 Whether a similar mechanism is operational in the heart is unclear. However, we showed that RITA is sufficient to induce cardiomyocyte differentiation without causing DNA damage, indicating that p53 is more important than DNA damage in the differentiation process. Furthermore, precise quantification of the number of presumed multipotent c-kit
does not show an acute reduction in the first 3 days after DOX stimulation. This was somewhat surprising given a previous report that showed reduced numbers of c-kit + cells after DOX treatment. 27 Important differences between that study and ours include the dose of DOX and the time point at which c-kit + cells were studied. Future studies will be necessary to determine how different pathological stimuli affect the overall abundance, turnover, and differentiation of c-kit + cells. Furthermore, it will be important to determine the precise mechanisms that favor specific lineage determination within c-kit + cells. One potential factor influencing the decision of ckit + cells to become endothelial cells or cardiomyocytes might be wall stress-mediated factors, although additional factors such as paracrine mediators may also be involved. 27, 39 Moreover, how these initiating factors in turn stimulate c-kit + CPCs to differentiate will be important to identify specific differentiation pathways that are relevant for adult CPCs. Identification of these pathways may further improve the efficacy of cell therapy, which is likely mediated by paracrine effectors that stimulate endogenous cells, such as c-kit + cells. 8 Although these results are promising for the role of p53 as an important mediator of cardiomyocyte commitment of c-kit + cells, the overall effect size is probably too small to be therapeutically relevant.
Last, it is well known that anthracyclines can cause both acute and late-onset cardiotoxicity, in part, because of the progressive loss of cardiomyocytes. We also observed significant cardiac dysfunction in response to DOX treatment. The overall increase in c-kit-derived cardiomyocytes in response to DOX is not sufficient to counteract the substantial loss of cardiomyocytes in the setting of acute cardiotoxicity. However, our study provides a platform for future studies to enhance the potential to generate new cardiomyocytes. By building on our results, future studies might further stimulate new cardiomyocyte formation without inducing substantial damage to the myocardium to add physiologically meaningful numbers of cardiomyocytes over the course of months rather than weeks.
There are some limitations to our study. Although we show that p53 is important in the differentiation of c-kit + cells toward cardiomyocytes, the observed effects fall short of a therapeutic benefit of cardiomyogenesis from c-kit + cell differentiation. The numbers of cardiomyocytes generated by c-kit + cells, as quantified from histological quantifications or isolated cardiomyocytes (<0.1%), are too low to give rise to meaningful regeneration. 40 A second limitation to our study is the lack of identifying a specific subpopulation of c-kit + cells that is predestined to become cardiomyocytes. If <1% of c-kit + cells are predestined to become cardiomyocytes, then we may have missed identification of this small population of c-kit + cells by sequencing only 400 cells or potentially because of size exclusion based on single-cell capture chip. However, other reports suggested that negative selection for CD45 enriches for cardiac cells that exhibit stem/ progenitor characteristics.
14 Despite using this exact approach, we failed to identify a specific population of c-kit + cells that expressed cardiomyocyte characteristic genes under homeostatic conditions. Although our approach of single-cell sequencing may have missed a small subpopulation of cells that is predestined to become cardiomyocytes, the results further substantiate the limited cardiomyogenic potential of c-kit + cells under homeostatic conditions. 41 In conclusion, we have identified p53 as a critical mediator of cardiomyocyte differentiation by endogenous c-kit + cells. Our findings are promising because they begin to show the circumstances under which endogenous cardiac c-kit + cells can generate cardiomyocytes, although the magnitude of new cardiomyocyte formation is currently too low to constitute a therapeutic effect of cardiomyogenesis from c-kit + cell differentiation. Nevertheless, this is an initial step toward the long-term goal of identifying strategies that enhance endogenous cardiac regeneration.
